Frontline Treatment Selection in EGFR-Mutated Metastatic NSCLC
Thoracic oncology experts debate frontline treatment strategies for patients with EGFR-mutated metastatic non-small cell lung cancer (NSCLC). Through three patient cases, faculty explore when to intensify treatment upfront, where osimertinib monotherapy may still have a role, and how clinical evidence and patient-specific factors influence selection among available combination regimens.
Round 1
Managing Patients With High Disease Burden
The debate begins with a patient with extensive, symptomatic metastatic disease. Faculty explore how tumor burden, the need for durable disease control, and treatment tolerability influence the decision to intensify therapy upfront.
Round 2
Managing Frontline Brain Metastases
The discussion turns to a patient with small, asymptomatic brain metastases and additional high-risk features. Faculty examine how CNS efficacy data, molecular characteristics, and the potential role of CNS-directed therapy influence frontline treatment selection.
Round 3
Establishing the Frontline Standard
In the final round, faculty consider a fit patient with relatively limited metastatic disease, exploring where osimertinib monotherapy may remain appropriate and how efficacy, tolerability, patient preferences, and treatment burden inform the decision to intensify treatment.
©️ 2026 HMP Global. All Rights Reserved.
This is a non-CME activity. The views and opinions expressed by the presenter(s) do not necessarily reflect the views and opinions of the Oncology Learning Network, HMP Global, or its employees and affiliates.
